TUSTIN, CA--(Marketwired - April 01, 2013) -
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM
), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 104th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 6-10, 2013 in Washington, DC. Data to be presented include studies investigating the immune stimulating mechanism of action of Peregrine's lead phosphatidylserine (PS)-targeting oncology clinical candidate bavituximab and the anti-tumor and imaging potential of other PS-targeting constructs.
Abstract Number 1244
Presentation Title: Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice
Presentation Time: Monday, Apr 08, 2013, 1:00 PM - 5:00 PM EDT
Location: Hall A-C, Poster Section 5
Poster Board Number: 24
Author Block: Yi Yin, Xianming Huang, Dan Ye, Philip Thorpe. UT Southwestern Medical Ctr., Dallas, TX
Abstract Number 2850
Presentation Title: Predicting anti-tumor responses to phosphatidylserine targeting antibodies using tumor imaging
Presentation Time: Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM EDT
Location: Hall A-C, Poster Section 21
Poster Board Number: 22
Author Block: Jian Gong(1), Richard Archer(1), Van Nguyen(1), Christopher C.W. Hughes(2), Jeff Hutchins(1), Bruce Freimark(1). 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. University of California, Irvine, Irvine, CA
Abstract Number: 4326
Presentation Title: Phosphatidylserine-targeting 'betabodies' for the treatment of cancer
Presentation Time: Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM EDT
Location: Hall A-C, Poster Section 36
Poster Board Number: 9
Author Block: Xianming Huang(1), Dan Ye(1), Troy Luster(2), E. Sally Ward(1), Philip Thorpe(1). 1. UT Southwestern Medical Ctr., Dallas, TX; 2. Human Genome Science, Maryland, MD
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.